Subtype
Breast Adenocarcinoma
CI-CAN-00002035Explore in graph →
686 active trials9 approved drugs104 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002035Explore in graph →
Clinical trials
1,713 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (278)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06955156 | Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC | unknown | Phase 2 | 50 | QIAO LIOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT04551495 | Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)(ROSALINE) | unknown | Phase 2 | 65 | Jules Bordet InstituteOTHER | 2 | Dec 4, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06355037 | Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT02993198 | A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging | unknown | Phase 2 | 134 | Northwestern UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT04418154 | Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients(NeoTENNIS) | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05145907 | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors | unknown | Phase 2 | 133 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT03639948 | Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer(NeoPACT) | unknown | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04739670 | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer(BELLA) | unknown | Phase 2 | 31 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03500380 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | unknown | Phase 2 / Phase 3 | 301 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03818685 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease(BreastImmune03) | unknown | Phase 2 | 95 | Centre Leon BerardOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05266937 | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel | unknown | Phase 2 | 49 | Consorzio OncotechOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04914390 | A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer(NeoATCT) | unknown | Phase 2 | 32 | Sichuan Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06210438 | SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases | unknown | Phase 2 | 24 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03812393 | Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast(FACT-2) | unknown | Phase 2 | 27 | West Cancer CenterOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04197687 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | unknown | Phase 2 | 480 | Academic and Community Cancer Research UnitedOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06154109 | Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial | unknown | Phase 2 | 90 | Zhiyu WangOTHER | 0 | Dec 1, 2023 | clinicaltrials |
| NCT05174832 | Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients | unknown | Phase 2 | 136 | Fudan UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05953168 | T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients | unknown | Phase 2 | 69 | Fudan UniversityOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05945368 | A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC | unknown | Phase 2 | 78 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03567720 | Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC | unknown | Phase 2 | 65 | OncoSec Medical IncorporatedINDUSTRY | 2 | Jun 1, 2023 | clinicaltrials |
| NCT05872412 | Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer | unknown | Phase 2 | 82 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05763992 | Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial(BREAKFAST-2) | unknown | Phase 2 | 145 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05556200 | A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs | unknown | Phase 2 | 58 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05746728 | Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer | unknown | Phase 1 / Phase 2 | 45 | Huihua XiongOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05670925 | A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. | unknown | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04997798 | Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02983071 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 4 | Feb 15, 2023 | clinicaltrials |
| NCT05453825 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | unknown | Phase 2 | 180 | OncXerna Theraputics, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT04248998 | Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer(BREAKFAST) | unknown | Phase 2 | 30 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04582968 | Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases | unknown | Phase 1 / Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03907800 | Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer(NeoPATH) | unknown | Phase 2 | 100 | Ruijin HospitalOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05085626 | Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05546255 | Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer | unknown | Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT03805399 | FUSCC Refractory TNBC Umbrella (FUTURE)(FUTURE) | unknown | Phase 1 / Phase 2 | 140 | Fudan UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04297267 | A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy(nonpCR GP) | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT05461690 | Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency | unknown | Phase 2 | 50 | Zhejiang Cancer HospitalOTHER | 0 | Jul 18, 2022 | clinicaltrials |
| NCT05429294 | Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038 | unknown | Phase 2 | 209 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT03913234 | Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 95 | Yonsei UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT04605575 | Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 | 208 | Sun Yat-sen UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346107 | PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer | unknown | Phase 2 | 100 | Xijing HospitalOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT04192903 | Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer | unknown | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04609215 | ImmunoBreast - A Phase Ib Study | unknown | Phase 1 / Phase 2 | 20 | Henrik DitzelOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04634747 | Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer | unknown | Phase 2 | 53 | OncoPep, Inc.INDUSTRY | 0 | Apr 20, 2022 | clinicaltrials |
| NCT04745975 | Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05334810 | DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer | unknown | Phase 2 | 191 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 19, 2022 | clinicaltrials |
Data updated 22 days agoSource updated May 2, 2025source: clinicaltrials